Open AccessTwo cases of anaphylaxis due to contrast media during administration of nivolumab and ipilimumab in metastatic renal cell carcinoma
Author(s) -
Kunihisa Nezu,
Hiromichi Katayama,
Atsushi Kyan
Publication year - 2019
Publication title -
international cancer conference journal
Language(s) - English
Resource type - Journals
ISSN - 2192-3183
DOI - 10.1007/s13691-019-00388-0
Subject(s) - nivolumab , ipilimumab , medicine , renal cell carcinoma , rash , anaphylaxis , adverse effect , melanoma , oncology , immunotherapy , radiology , gastroenterology , cancer , immunology , allergy , cancer research
A combination therapy of nivolumab and ipilimumab is effective for advanced renal cell carcinoma, but there are concerns about immune-related adverse events. A 46-year-old man was hospitalized for metastatic renal cell carcinoma. On day 9, he received nivolumab and ipilimumab. On days 16 and 49, he presented with fever, skin rash, and hypotension after contrast-enhanced computed tomography. A 70-year-old man was hospitalized for metastatic renal cell carcinoma. On day 9, he received nivolumab and ipilimumab. On day 44, he presented with fever, skin rash, and hypotension after contrast-enhanced computed tomography. Both patients were diagnosed with anaphylaxis due to the contrast agent.